These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 25698486

  • 1. Comparative evaluation of the protective efficacy of two formulations of a recombinant Chlamydia abortus subunit candidate vaccine in a mouse model.
    Pan Q, Pais R, Ohandjo A, He C, He Q, Omosun Y, Igietseme JU, Eko FO.
    Vaccine; 2015 Apr 08; 33(15):1865-72. PubMed ID: 25698486
    [Abstract] [Full Text] [Related]

  • 2. Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus Vaccine.
    Richardson S, Medhavi F, Tanner T, Lundy S, Omosun Y, Igietseme JU, Carroll D, Eko FO.
    Front Immunol; 2021 Apr 08; 12():698737. PubMed ID: 34249004
    [Abstract] [Full Text] [Related]

  • 3. Chlamydia abortus Pmp18.1 Induces IL-1β Secretion by TLR4 Activation through the MyD88, NF-κB, and Caspase-1 Signaling Pathways.
    Pan Q, Zhang Q, Chu J, Pais R, Liu S, He C, Eko FO.
    Front Cell Infect Microbiol; 2017 Apr 08; 7():514. PubMed ID: 29326885
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge.
    Pal S, Tatarenkova OV, de la Maza LM.
    Immunology; 2015 Nov 08; 146(3):432-43. PubMed ID: 26423798
    [Abstract] [Full Text] [Related]

  • 7. A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin.
    Ekong EE, Okenu DN, Mania-Pramanik J, He Q, Igietseme JU, Ananaba GA, Lyn D, Black C, Eko FO.
    FEMS Immunol Med Microbiol; 2009 Mar 08; 55(2):280-91. PubMed ID: 19040663
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate.
    Eko FO, Okenu DN, Singh UP, He Q, Black C, Igietseme JU.
    Vaccine; 2011 May 12; 29(21):3802-10. PubMed ID: 21421002
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of an ompA-based phage-mediated DNA vaccine against Chlamydia abortus in piglets.
    Ou C, Tian D, Ling Y, Pan Q, He Q, Eko FO, He C.
    Int Immunopharmacol; 2013 Aug 12; 16(4):505-10. PubMed ID: 23669337
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine.
    Ifere GO, He Q, Igietseme JU, Ananaba GA, Lyn D, Lubitz W, Kellar KL, Black CM, Eko FO.
    J Microbiol Immunol Infect; 2007 Jun 12; 40(3):188-200. PubMed ID: 17639158
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Vaccination with the polymorphic membrane protein A reduces Chlamydia muridarum induced genital tract pathology.
    Müller T, Becker E, Stallmann S, Waldhuber A, Römmler-Dreher F, Albrecht S, Mohr F, Hegemann JH, Miethke T.
    Vaccine; 2017 May 15; 35(21):2801-2810. PubMed ID: 28413133
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.
    Sun G, Pal S, Weiland J, Peterson EM, de la Maza LM.
    Vaccine; 2009 Aug 06; 27(36):5020-5. PubMed ID: 19446590
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge.
    Pal S, Tifrea DF, Follmann F, Andersen P, de la Maza LM.
    Vaccine; 2017 Mar 23; 35(13):1705-1711. PubMed ID: 28238632
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.